C4 Therapeutics, Inc. (CCCC)
3.10
+0.15
(+5.08%)
USD |
NASDAQ |
Nov 06, 16:00
3.09
-0.01
(-0.32%)
After-Hours: 20:00
C4 Therapeutics Shareholders Equity (Quarterly) : 228.17M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 228.17M |
| June 30, 2026 | 247.26M |
| March 31, 2026 | 234.25M |
| December 31, 2025 | 256.59M |
| September 30, 2025 | 154.41M |
| June 30, 2025 | 174.06M |
| March 31, 2025 | 195.14M |
| December 31, 2024 | 215.99M |
| September 30, 2024 | 242.66M |
| June 30, 2024 | 247.06M |
| March 31, 2024 | 258.28M |
| December 31, 2023 | 246.11M |
| September 30, 2023 | 216.02M |
| June 30, 2023 | 233.71M |
| Date | Value |
|---|---|
| March 31, 2023 | 262.47M |
| December 31, 2022 | 289.23M |
| September 30, 2022 | 318.18M |
| June 30, 2022 | 344.59M |
| March 31, 2022 | 364.53M |
| December 31, 2021 | 389.61M |
| September 30, 2021 | 398.78M |
| June 30, 2021 | 416.43M |
| March 31, 2021 | 263.70M |
| December 31, 2020 | 280.79M |
| September 30, 2020 | 100.60M |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | -0.968M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Intellia Therapeutics, Inc. | 613.09M |
| Kymera Therapeutics, Inc. | 1.615B |
| NKGen Biotech, Inc. | -- |
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 331.80M |
| Total Liabilities (Quarterly) | 103.63M |
| Debt to Equity Ratio | 0.2421 |
| Current Ratio | 5.174 |
| Net Debt Paydown Yield | 0.35% |